PMV Pharmaceuticals, Inc.
NASDAQ:PMVPBiotechnology
+$0.04 today
- Market cap
- $65.06M
- Beta
- 1.36
- P/E (TTM)
- -0.8
- EPS (TTM)
- -$1.47
Volume 0.43M
Average 0.38M
PMVP Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
PMV Pharmaceuticals, Inc.NASDAQ: PMVP
Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026
Change in working capital growth accelerates
Q1 FY2026 change in working capital of $2.66M (cash outflow) rose 73.1% year over year, ahead of the -78.2% change in trailing-twelve-month change in working capital.
Context
- Change in working capital increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +73.1% holds above the trailing-twelve-month pace of -78.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- 914K USD
- Year-over-year change
- +157.4%
- 4-year CAGR
- -31.4%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 914K | +157.4% |
| FY2024 | 2024-12-31 | (1.59M) | -129.3% |
| FY2023 | 2023-12-31 | 5.43M | +1055.5% |
| FY2022 | 2022-12-31 | (568K) | -113.8% |
| FY2021 | 2021-12-31 | 4.12M | — |
Change in Working Capital vs competitors
How PMVP compares with its peers on the latest reported figures
- PMVP's LTM Mar 2026 change in working capital of $208K is the smallest of the 9 companies compared; the peer median is $3.46M.
- Its year-over-year change of -78.2% is the 5th highest of 9, against a peer median of -120.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $35.96M | -1082.5% | +68.7% | 14.1% | |
| LTM Mar 2026 | $10.92M | +78.7% | -42.2% | — | |
| LTM Mar 2026 | $10.69M | -1471.6% | +21.1% | 117.0% | |
| LTM Mar 2026 | $5.86M | +748.8% | — | 3083.7% | |
| LTM Mar 2026 | $5.78M | +183.1% | — | — | |
CBUSCibus, Inc. | LTM Mar 2026 | $4.35M | -199.8% | — | 101.6% |
| LTM Mar 2026 | $3.84M | -41.3% | — | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $3.08M | -227.9% | +16.6% | — |
| LTM Mar 2026 | $208K | -78.2% | — | — | |
| Peer median (excluding PMVP) | $3.46M | -120.6% | +18.8% | 109.3% | |
Competitors are the stored peer set for PMVP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (57.85M) | (73.32M) | (68.96M) | (58.71M) | (77.74M) |
| Depreciation & Amortization | 1.28M | 650K | 1.26M | 1.14M | 133K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.34M | 10.2M | 12.38M | 8.87M | 5.92M |
| Change in Working Capital | 4.12M | (568K) | 5.43M | (1.59M) | 914K |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 191K | (389K) | 235K | 3.34M | (3.42M) |
| Other Working Capital | 3.93M | (179K) | 5.19M | (4.93M) | 4.34M |
| Other Non-Cash Items | 5.87M | 9.48M | (5.76M) | (997K) | (2.81M) |
| Operating Cash Flow | (46.57M) | (63.76M) | (55.66M) | (51.28M) | (73.58M) |
| Capital Expenditures | (1.35M) | (7.98M) | (962K) | (655K) | (29K) |
| Acquisitions (Net) | 0 | 0 | 0 | 251K | 31K |
| Purchases of Investments | (256.85M) | (229.2M) | (220.54M) | (148.29M) | (88.2M) |
| Sales of Investments | 114.61M | 235.82M | 170.96M | 202.04M | 158.37M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (143.58M) | (1.37M) | (50.55M) | 53.35M | 70.17M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 2.02M | 958K | 35.12M | 313K | 505K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 456K | 0 | 0 |
| Financing Cash Flow | 2.02M | 958K | 35.58M | 313K | 505K |
| Effect of Forex Changes | 1 | 0 | 34K | (35K) | 7K |
| Net Change in Cash | (188.13M) | (64.17M) | (70.59M) | 2.35M | (2.89M) |
| Free Cash Flow | (47.92M) | (71.74M) | (56.62M) | (51.94M) | (73.61M) |
PMV Pharmaceuticals, Inc.
NASDAQ:PMVP
Intrinsic Alpha fair value
Locked
Current Price
$1.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.